ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Saturday, 21 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call Transcript

Viyash Scientific Earnings Call Transcript: Key Takeaways

Q2 revenue ₹988 Cr (+16.2%) and PAT ₹85 Cr (+16.1%) are real but base-aided. Q2 EBITDA margin fell to 21.1% from 22.1%, and management leans on 2028-30 launches.

Viyash Scientific Q2 FY27 concall: date, live audio and summaryConcall page →
Guidance and delivery
Management target Net Profit 50.0% FY27
Highlights
Revenue growthQ2 +16.2% YoY, +4.4% QoQ; H1 +17.8%.
MarginsQ2 EBITDA margin 21.1% vs 22.1% YoY; H1 up to 21.3%.
Demand visibilityAPI H2 visibility strong; animal health guided 20%+ growth.
Management confidenceUpbeat; 'strong' repeated, hedged on US and human health.

Growth

Q2 revenue +16.2% YoY and +4.4% QoQ; H1 +17.8%. US sales fell YoY against a one-off exclusivity quarter last year.

Outlook

Guides PAT growth above 50% in FY27 (H1 +49%). Capex ~₹150 Cr over two years. ₹20 Cr loan prepayment considered; Europe launch next year.

Risks

Q2 gross margin 53.7% vs 55.5%. Q2 ESOP cost ~₹42 Cr, with ~₹40 Cr/quarter expected. Human health launches delayed; 2029-30 pipeline unproven.

Last quarter's promises, checked

Delivered

  • Rev growth 13-15% → H1 +17.8% (= BEAT)
  • API growth 13-14% → Q2 API ~20% (= BEAT)
  • BFL close in 2-3 mths → acquired (= BEAT)

Partly delivered

  • EBITDA margin 20-22% → Q2 21.1%, down from 22.1% (= PARTIAL)
  • Animal Health 20%+ → companion ~60%; total n/a (= PARTIAL)

Missed

  • Capex ₹250-300Cr/yr → ~₹150Cr over 2 yrs (= MISS)
  • Q2 ESOP ₹40Cr → ₹42Cr (= MISS)
  • 1-2 Human launches FY27 → delayed (= MISS)
Source

Earnings Call Transcript filed with NSE, NSE: VIYASH. Summary written with AI assistance from the document.

Read the document ↗

Viyash Scientific Ltd: key numbers

Share price
₹233.36
Market cap
₹10,314 Cr
Revenue (annual)
₹3,420 Cr
Net profit (annual)
₹177.3 Cr
P/E (TTM)
44.4×Sector 49.0×
Promoter holding
49.24%-12.07% QoQ
FII holding
2.60%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Viyash Scientific Ltd

All →